| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $75,770 | 6 | 33 |
Sells | $522,950 | 12 | 67 |
| BIENAIME JEAN JACQUES | director | 6 | $75,770 | 0 | $0 | $75,770 |
| Newton Charles W. | director | 0 | $0 | 2 | $11,197 | $-11,197 |
| Tanini Annita | Corp. Controller & VP, Finance | 0 | $0 | 1 | $12,595 | $-12,595 |
| Seth Alpna | director | 0 | $0 | 1 | $28,140 | $-28,140 |
| Farzan Nima | director | 0 | $0 | 1 | $28,166 | $-28,166 |
| Knowles Julius | director | 0 | $0 | 1 | $28,166 | $-28,166 |
| Regnante Keith | CHIEF FINANCIAL OFFICER | 0 | $0 | 1 | $77,483 | $-77,483 |
| Lerner Lorena Raquel | Chief Science Officer | 0 | $0 | 2 | $100,038 | $-100,038 |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER | 0 | $0 | 1 | $113,433 | $-113,433 |
| Cho Esther | SVP, General Counsel | 0 | $0 | 2 | $123,731 | $-123,731 |
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing …
Over the last 12 months, insiders at Keros Therapeutics, Inc. have bought $75,770 and sold $522,950 worth of Keros Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Keros Therapeutics, Inc. have bought $4.77M and sold $10.77M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BIENAIME JEAN JACQUES (director) — $75,770.
The last purchase of 1,000 shares for transaction amount of $10,270 was made by BIENAIME JEAN JACQUES (director) on 2026‑08‑17.
| 2026-08-18 | Sale | Tanini Annita | Corp. Controller & VP, Finance | 1,224 0.0037% | $10.29 | $12,595 | +5.75% | |
| 2026-08-18 | Sale | Cho Esther | Chief Legal Officer | 4,485 0.0136% | $10.29 | $46,151 | +5.75% | |
| 2026-08-18 | Sale | Lerner Lorena Raquel | Chief Scientific Officer | 3,568 0.0108% | $10.29 | $36,715 | +5.75% | |
| 2026-08-18 | Sale | Newton Charles W. | director | 551 0.0017% | $10.30 | $5,675 | +5.75% | |
| 2026-08-17 | BIENAIME JEAN JACQUES | director | 1,000 0.0049% | $10.27 | $10,270 | +6.97% | ||
| 2026-07-15 | BIENAIME JEAN JACQUES | director | 1,000 0.003% | $10.61 | $10,610 | +0.68% | ||
| 2026-06-15 | BIENAIME JEAN JACQUES | director | 1,000 0.0031% | $10.19 | $10,190 | +8.15% | ||
| 2026-06-11 | Sale | Newton Charles W. | director | 550 0.0017% | $10.04 | $5,522 | +10.10% | |
| 2026-06-04 | Sale | Knowles Julius | director | 2,625 0.0082% | $10.73 | $28,166 | +2.51% | |
| 2026-06-04 | Sale | Seth Alpna | director | 2,625 0.0082% | $10.72 | $28,140 | +2.51% | |
| 2026-06-04 | Sale | Farzan Nima | director | 2,625 0.0082% | $10.73 | $28,166 | +2.51% | |
| 2026-05-15 | BIENAIME JEAN JACQUES | director | 1,000 0.0031% | $10.58 | $10,580 | +5.10% | ||
| 2026-04-15 | BIENAIME JEAN JACQUES | director | 1,000 0.0027% | $11.70 | $11,700 | -5.21% | ||
| 2026-03-09 | BIENAIME JEAN JACQUES | director | 2,000 0.0053% | $11.21 | $22,420 | -2.07% | ||
| 2026-02-19 | Sale | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | 7,015 0.0173% | $16.17 | $113,433 | -32.51% | |
| 2026-02-18 | Sale | Cho Esther | SVP, General Counsel | 4,745 0.0118% | $16.35 | $77,581 | -30.92% | |
| 2026-02-18 | Sale | Regnante Keith | CHIEF FINANCIAL OFFICER | 4,739 0.0118% | $16.35 | $77,483 | -30.92% | |
| 2026-02-18 | Sale | Lerner Lorena Raquel | Chief Science Officer | 3,873 0.0097% | $16.35 | $63,324 | -30.92% | |
| 2025-10-15 | Sale | Pontifax Management 4 G.P. (2015) Ltd. | 10 percent owner | 155,262 0.4683% | $17.75 | $2.76M | -20.08% | |
| 2025-10-15 | Sale | ADAR1 Capital Management, LLC | 10 percent owner | 743,358 2.1529% | $17.75 | $13.19M | -20.08% |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER | 385708 1.9453% | $4.18M | 1 | 1 | +122.73% |
| BIENAIME JEAN JACQUES | director | 19592 0.0988% | $212,181.36 | 6 | 0 | |
| Knowles Julius | director | 10958 0.0553% | $118,675.14 | 1 | 39 | +122.73% |
| Kariv Tomer | 2288151 11.5405% | $24.78M | 2 | 0 | +51.74% | |
| Nussbaum Ran | 2288151 11.5405% | $24.78M | 2 | 0 | +51.74% | |
| Lazarus Alon | 2013102 10.1532% | $21.8M | 1 | 0 | +122.73% | |
| Arkin Bio Ventures Limited Partnership | 10 percent owner | 2013102 10.1532% | $21.8M | 1 | 0 | +122.73% |
| ORBIMED ADVISORS LLC | director | 119522 0.6028% | $1.29M | 1 | 1 | +122.73% |
| GORDON CARL L | director | 119522 0.6028% | $1.29M | 1 | 1 | +122.73% |
| Pontifax Management 4 G.P. (2015) Ltd. | 10 percent owner | 0 0% | $0 | 2 | 1 | +51.74% |
| ADAR1 Capital Management, LLC | 10 percent owner | 0 0% | $0 | 1 | 1 | +45.5% |
$22,710,871 | 107 | 8.53% | $220.62M | |
$6,146,922 | 96 | -4.70% | $233.68M | |
$19,239,249 | 50 | -2.24% | $238.33M | |
$168,352,523 | 35 | 13.58% | $218.79M | |
$54,828,550 | 26 | -13.88% | $201.12M |
| Increased Positions | 85 | +41.26% | 5M | +15.53% |
| Decreased Positions | 97 | -47.09% | 20M | -57.95% |
| New Positions | 45 | New | 1M | New |
| Sold Out Positions | 25 | Sold Out | 7M | Sold Out |
| Total Postitions | 194 | -5.83% | 20M | -42.42% |
| Adar1 Capital Management, Llc | $99,917.00 | 17.96% | 5.39M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $50,406.00 | 9.06% | 2.72M | +87,129 | +3.31% | 2025-09-30 |
| Blackrock, Inc. | $50,376.00 | 9.06% | 2.72M | -15,470 | -0.57% | 2025-09-30 |
| Madison Avenue Partners, Lp | $50,210.00 | 9.03% | 2.71M | +16,753 | +0.62% | 2025-09-30 |
| Western Standard Llc | $40,600.00 | 7.3% | 2.19M | +654,989 | +42.67% | 2025-09-30 |
| Tang Capital Management Llc | $26,308.00 | 4.73% | 1.42M | 0 | 0% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $24,685.00 | 4.44% | 1.33M | +34,042 | +2.62% | 2025-09-30 |
| Goldman Sachs Group Inc | $24,574.00 | 4.42% | 1.33M | +441,923 | +50.02% | 2025-09-30 |
| State Street Corp | $24,157.00 | 4.34% | 1.3M | -81,276 | -5.87% | 2025-09-30 |
| Nantahala Capital Management, Llc | $22,863.00 | 4.11% | 1.23M | -387,503 | -23.91% | 2025-09-30 |